ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 136 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2017. The put-call ratio across all filers is 3.87 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $44,425 | -74.5% | 27,940 | 0.0% | 0.00% | – |
Q4 2022 | $174,066 | -1.3% | 27,940 | +6.2% | 0.00% | – |
Q3 2022 | $176,270 | +4.3% | 26,309 | -1.0% | 0.00% | – |
Q2 2022 | $168,947 | +42.6% | 26,564 | +4.0% | 0.00% | – |
Q1 2022 | $118,496 | +97.5% | 25,538 | +114.3% | 0.00% | – |
Q4 2021 | $60,000 | -67.0% | 11,917 | -21.1% | 0.00% | – |
Q3 2021 | $182,000 | -44.5% | 15,098 | -2.5% | 0.00% | – |
Q2 2021 | $328,000 | -22.3% | 15,492 | +3.0% | 0.00% | – |
Q1 2021 | $422,000 | +2.2% | 15,045 | -5.3% | 0.00% | – |
Q4 2020 | $413,000 | -26.9% | 15,894 | +4.6% | 0.00% | -100.0% |
Q3 2020 | $565,000 | -23.3% | 15,200 | -1.8% | 0.00% | 0.0% |
Q2 2020 | $737,000 | +44.5% | 15,474 | -4.3% | 0.00% | 0.0% |
Q1 2020 | $510,000 | -43.3% | 16,161 | +7.2% | 0.00% | 0.0% |
Q4 2019 | $899,000 | +52.4% | 15,082 | -3.4% | 0.00% | 0.0% |
Q3 2019 | $590,000 | -19.0% | 15,615 | -0.2% | 0.00% | 0.0% |
Q2 2019 | $728,000 | +19.1% | 15,641 | +2.8% | 0.00% | 0.0% |
Q1 2019 | $611,000 | -5.7% | 15,214 | +8.0% | 0.00% | 0.0% |
Q4 2018 | $648,000 | -4.6% | 14,081 | -7.9% | 0.00% | 0.0% |
Q3 2018 | $679,000 | -0.4% | 15,296 | -12.1% | 0.00% | 0.0% |
Q2 2018 | $682,000 | -28.1% | 17,403 | +32.7% | 0.00% | 0.0% |
Q1 2018 | $949,000 | +9.5% | 13,116 | -0.3% | 0.00% | 0.0% |
Q4 2017 | $867,000 | +32.4% | 13,155 | +0.5% | 0.00% | 0.0% |
Q3 2017 | $655,000 | +19.3% | 13,095 | +10.5% | 0.00% | 0.0% |
Q2 2017 | $549,000 | +27.1% | 11,847 | -3.0% | 0.00% | 0.0% |
Q1 2017 | $432,000 | +206.4% | 12,208 | +8.7% | 0.00% | – |
Q4 2016 | $141,000 | -10.2% | 11,226 | -1.3% | 0.00% | – |
Q3 2016 | $157,000 | +44.0% | 11,378 | +3.7% | 0.00% | – |
Q2 2016 | $109,000 | -27.3% | 10,970 | +20.4% | 0.00% | – |
Q1 2016 | $150,000 | -22.7% | 9,114 | +4.2% | 0.00% | – |
Q4 2015 | $194,000 | -5.8% | 8,746 | 0.0% | 0.00% | – |
Q3 2015 | $206,000 | -93.7% | 8,746 | -78.1% | 0.00% | -100.0% |
Q2 2015 | $3,266,000 | +735.3% | 39,939 | +846.6% | 0.00% | – |
Q1 2015 | $391,000 | +131.4% | 4,219 | +1.0% | 0.00% | – |
Q4 2014 | $169,000 | +482.8% | 4,176 | +258.1% | 0.00% | – |
Q3 2014 | $29,000 | – | 1,166 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |